Skip to main content

Table 1 Major cancer immunotherapeutics approved by the US Food and Drug Administration (FDA)

From: New opportunities for nanoparticles in cancer immunotherapy

Drug
(Trade Name)
Drug Type
(Target)
Targeted Cancer FDA Approval
Date
Ipilimumab
(Yervoy®)
Monoclonal antibody
(CTLA-4)
Advanced melanoma March 2011
Pembrolizumab
(Keytruda®)
Monoclonal antibody
(PD-1)
Advanced refractory melanoma and non–small cell lung cancer September 2014
Nivolumab
(Opdivo®)
Monoclonal antibody
(PD-1)
Unresectable or metastatic melanoma squamous non–small cell lung cancer December 2014
Atezolizumab
(Tecentriq®)
Monoclonal antibody
(PD-L1)
Locally advanced or metastatic bladder cancer May 2016
Avelumab
(Bavencio®)
Monoclonal antibody
(PD-L1)
Locally advanced or metastatic bladder cancer May 2017
Durvalumab
(Imfinzi®)
Monoclonal antibody
(PD-L1)
Locally advanced or metastatic bladder cancer May 2017
  1. CTLA-4 cytotoxic T lymphocyte–associated protein-4, PD-1 programmed cell death-1, PD-L1 programmed cell death ligand-1